• Formazione
  • Protocolli Covid-19
  • A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)

Gilead Sciences, Inc - 11.03.202

(Data Parere Unico CE 11-03-2020)

GS-US-540-5773 documenti